Brind.

Chinese Medicine Maker Announces Clinical Trial in Singapore

4 reports, 1 independent Updated Oct 19
Gone quiet Reached 4 outlets in its first 24 hours
Reports
4
Developments
1
Repetition
75%

New informationRepeats or wire copies

AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Wang Lei, chairman of Tianjin Pharmaceutical Group, hosted the 23rd World Congress of Chinese Medicine in Singapore on October 19, 2026. During the event, Da Ren Tang announced a collaboration with Singapore General Hospital to conduct an international randomized, double-blind, controlled trial of its heart remedy, Suxiao Jiuxin Pills.

From vietnamnews.vn

Why it matters

Some supportBrind's analysis of the reports

The study marks the first time a Chinese proprietary medicine has undergone clinical trials at a major Western-medicine hospital in Singapore. Wang Lei noted that the holistic approach of Chinese medicine could offer an advantage in strengthening public health systems.

From vietnamnews.vn

Who's involved

  • Wang LeiHosted the World Congress and announced the international clinical trial collaboration.
  • SingaporeLocation where the World Congress was held.
  • Singapore General HospitalPartnering with Da Ren Tang to conduct the international clinical trial.

Keep exploring

The entities involved

Coverage

Newest first; wire copies grouped
3 more outlets ran the same wire story